XM does not provide services to residents of the United States of America.
S
S

Sobi


News

SOBI's Phase 3 Trial Of Doptelet For Pediatric ITP Shows Positive results

BRIEF-SOBI's Phase 3 Trial Of Doptelet For Pediatric ITP Shows Positive results March 25 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : POSITIVE RESULTS FROM PHASE 3 STUDY OF DOPTELET FOR TREATMENT OF CHILDREN AND ADOLESCENTS WITH ITP ON PHASE 3 STUDY OF DOPTELET: PRIMARY ENDPOINT WAS MET Further company coverage: SOBIV.ST (Gdansk Newsro
S

Profit inflection ahead - Berenberg starts Sobi with 'buy'

BUZZ-Profit inflection ahead - Berenberg starts Sobi with 'buy' ** Berenberg initiates coverage of the pharmaceutical group Swedish Orphan Biovitrum (Sobi) SOBIV.ST with "buy" rating, target price of SEK 315 ahead of profit inflection ** It sees the company set to deliver double-digit revenue growth and margin expansion driven by new drug launches
S

Edpr, ENI, Repsol

EUROPE RESEARCH ROUNDUP-Edpr, ENI, Repsol Feb 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Edpr, ENI and Repsol, on Thursday. HIGHLIGHTS * Digital Workforce Services Oyj DWFS.HE : Inderes cuts to reduce from accumulate * Edpr EDPR.LS : Exane BNP Paribas raises to outperform from neutral * ENI ENI.MI : Exane BNP Paribas cuts to underperform from neutral * Repsol REP.MC : Exane BNP Paribas raises to outperform from neutral * So
A
A
A
A
B
C
C
D
E
E
E
E
F
G
H
H
H
K
M
M
S
U
D
E

Swedish Orphan Biovitrum, Handok Establish Joint Venture In South Korea

BRIEF-Swedish Orphan Biovitrum, Handok Establish Joint Venture In South Korea Feb 13 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : CO, HANDOK ESTABLISH JV FOR RARE DISEASE BUSINESS IN SOUTH KOREA JV TO COMMERCIALISE, DISTRIBUTE SELECTED SOBI MEDICINES IN SOUTH KOREA JV IS DUE FOR INCORPORATION IN H1 Source text for Eikon: [ID:] Further
S

Adyen, AstraZeneca, Bellway

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Bellway Feb 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Adyen, AstraZeneca and Bellway, on Friday. HIGHLIGHTS * Adyen NV ADYEN.AS : TD Cowen raises to outperform from market perform * AstraZeneca AZN.L : Deutsche Bank cuts to sell from hold * Bellway Plc BWY.L : Peel Hunt cuts to hold from buy * Boliden AB BOL.ST : Berenberg raises to hold from sell * Eutelsat Communications ETL.PA :
A
A
B
B
B
B
B
C
C
D
E
E
E
E
G
H
H
H
K
N
P
P
R
S
S
S
A
A
B
B

Sobi falls on Q4 profit, 2024 outlook below estimates as costs weigh

BUZZ-Sobi falls on Q4 profit, 2024 outlook below estimates as costs weigh ** Shares in Swedish Orphan Biovitrum (Sobi) SOBIV.ST fall over 6% after the pharmaceutical group posted Q4 results and 2024 outlook below estimates ** The company expects 2024 sales to grow in a high single-digit percentage, with adj. EBITA margin in a mid-30% range ** RBC a
S

Sobi Sees 2024 Adj EBITA Margin In Mid-30s Percentage Of Revenue

BRIEF-Sobi Sees 2024 Adj EBITA Margin In Mid-30s Percentage Of Revenue Feb 8 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : OUTLOOK 2024: REVENUE IS ANTICIPATED TO GROW BY A HIGH SINGLE-DIGIT PERCENTAGE AT CER OUTLOOK 2024: EBITA MARGIN ADJUSTED IS ANTICIPATED TO BE IN THE MID-30S PERCENTAGE OF REVENUE NO DIVIDEND WILL BE PAID FOR 2023 S
S

Close Brothers Group, IMCD, Swedish Orphan Biovitrum

EUROPE RESEARCH ROUNDUP-Close Brothers Group, IMCD, Swedish Orphan Biovitrum Feb 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Close Brothers Group, IMCD and Swedish Orphan Biovitrum, on Friday. HIGHLIGHTS * Close Brothers Group Plc CBRO.L : RBC cuts to sector perform from outperform * DCC DCC.L : Berenberg raises target price to 7,020p from 6,520p * IMCD IMCD.AS : HSBC cuts to hold from buy * OCI NV OCI.AS : Berenberg raises t
A
B
C
C
C
C
D
D
D
D
D
G
I
K
L
L
L
M
S
S
S
H
A
A
B
F
F
J
W

SOBI Chairman Resigns Due To Health Reasons

BRIEF-SOBI Chairman Resigns Due To Health Reasons Jan 5 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI'S CHAIRMAN OF THE BOARD RESIGNS DUE TO HEALTH REASONS SOBI'S CHAIRMAN OF BOARD RESIGNS DUE TO HEALTH REASONS Source text for Eikon: ID:nWkr7yFd22 Further company coverage: SOBIV.ST (Gdansk Newsroom)
S

Lawyer who used firm's data to trade on pharma deal gets 2-month sentence

Lawyer who used firm's data to trade on pharma deal gets 2-month sentence By David Thomas Dec 20 (Reuters) - A federal judge in Washington, D.C. on Wednesday sentenced a Brazilian lawyer to two months in prison after he pleaded guilty to trading on inside information while he was serving as a visiting attorney at U.S. law firm Gibson, Dunn & Crutcher.
S

Shionogi & Co: Shionogi And SOBI Have Signed Distribution Agreement For Cefiderocol Covering 13 Countries In Central & Eastern Europe

BRIEF-Shionogi & Co: Shionogi And SOBI Have Signed Distribution Agreement For Cefiderocol Covering 13 Countries In Central & Eastern Europe Dec 18 (Reuters) - Shionogi & Co Ltd 4507.T : SHIONOGI & CO - SHIONOGI AND SOBI HAVE SIGNED DISTRIBUTION AGREEMENT FOR CEFIDEROCOL COVERING 13 COUNTRIES IN CENTRAL & EASTERN EUROPE Source text: https://www.shio
S

Elia Group, Koninklijke Ahold, Oxford Instruments

EUROPE RESEARCH ROUNDUP-Elia Group, Koninklijke Ahold, Oxford Instruments Nov 15 (Reuters) - ṄSecurities analysts revised their ratings and price targets on several European companies, including Elia Group, Koninklijke Ahold and Oxford Instruments, on Wednesday. HIGHLIGHTS * Compass Group CPG.L : Deutsche Bank raises to buy from hold * Elia Group SA ELI.BR : Citigroup raises to buy from neutral * Koninklijke Ahold AD.AS : Morgan Stanley cuts to equal-weight from overweight * Oxford Instruments
B
B
C
C
H
H
I
I
J
K
N
O
P
R
R
S
S
T
V
A
E
I
N
R

AstraZeneca prioritizes US for RSV drug amid surge in cases

AstraZeneca prioritizes US for RSV drug amid surge in cases By Patrick Wingrove and Maggie Fick NEW YORK, Nov 10 (Reuters) - AstraZeneca AZN.L on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.
A
S
S

Brazilian lawyer pleads guilty to insider trading while at Gibson Dunn law firm

Brazilian lawyer pleads guilty to insider trading while at Gibson Dunn law firm By David Thomas Nov 1 (Reuters) - A Brazilian lawyer pleaded guilty in U.S. court on Wednesday to insider trading after profiting off information about a $1.7 billion deal involving a client of his former law firm, Gibson, Dunn & Crutcher. Romero Cabral da Costa Neto, 33, entered his guilty plea in Washington, D.C., federal court, two months after his arrest .
S

European shares rise as bond yields retreat, Big Pharma rallies

UPDATE 2-European shares rise as bond yields retreat, Big Pharma rallies For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window German economy shrinks slightly in Q3 Sanofi recovers, boosts healthcare stocks ArcelorMittal falls, confirms talks to nationalize Kazakh unit HSBC slides as Q3 profit disappoints STOXX 600 up 0.4% Updated at 1648 GMT By Ankika Biswas and Bansari Mayur Kamdar Oct 30 (Reuters) - European shares began the week on a stron
A
D
H
I
S
S
E
F
U
G

Sobi rises on Q3 beat driven by Beyfortus, key products

BUZZ-Sobi rises on Q3 beat driven by Beyfortus, key products ** Shares in drugmaker Swedish Orphan Biovitrum (SOBI) SOBIV.ST rise more than 4% after its Q3 results beat expectations ** Its quarterly revenue came to SEK 5.17 bln ($462.85 mln), beating the IBES estimate of SEK 4.52 bln with Haematology and Immunology sales rising year-on-year ** Also
S
S

SOBI Keeps 2023 Outlook Unchanged

BRIEF-SOBI Keeps 2023 Outlook Unchanged Oct 30 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : OUTLOOK 2023 UNCHANGED Q3 IMMUNOLOGY REVENUE SEK 1,400 MILLION VERSUS SEK 1,070 MILLION YEAR AGO Q3 HAEMATOLOGY REVENUE SEK 3,484 MILLION VERSUS SEK 2,619 MILLION YEAR AGO TOP-LINE GREW IN THE THIRD QUARTER DUE TO RISING REVENUE FROM HAEMATOLOGY
S

Sobi rises on royalty read-across from Sanofi sales

BUZZ-Sobi rises on royalty read-across from Sanofi sales ** Shares in drugmaker Swedish Orphan Biovitrum (SOBI) SOBIV.ST rise 3% after Sanofi SASY.PA updated the market on sales of products where SOBI earns royalties ** RBC said before the bell that it expected positive product read-across for SOBI after updates in Sanofi's Q3 report ** Sanofi says Q3 sales of Beyfortus in the U.S.
S
S

Sanofi seeing 'unprecedented' demand for RSV therapy

CORRECTED-UPDATE 1-Sanofi seeing 'unprecedented' demand for RSV therapy Corrects Oct 20 story in paragraphs 1, 2, 5 to show the drug was co-developed by Sanofi and AstraZeneca Oct 20 (Reuters) - French drugmaker Sanofi SASY.PA said on Friday it was seeing an "unprecedented level" of demand for an antibody therapy it co-developed to prevent respiratory syncytial virus (RSV), a leading cause of hospitalizations in infants.
A
S
S

SOBI Reports Positive Phase 2 Results for Pegcetacoplan in Post-Transplant Mpgn, C3g

BRIEF-SOBI Reports Positive Phase 2 Results for Pegcetacoplan in Post-Transplant IC-Mpgn, C3g Oct 17 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST : SOBI ANNOUNCES POSITIVE PHASE 2 NOBLE RESULTS OF PEGCETACOPLAN IN POST-TRANSPLANT RECURRENCE OF PRIMARY IC-MPGN AND C3G AFTER 12 WEEKS, 50% OF PATIENTS TREATED WITH PEGCETACOPLAN SHOWED A RED
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.